UPLIZNA® (INEBILIZUMAB-CDON) SIGNIFICANTLY IMPROVES GENERALIZED MYASTHENIA GRAVIS SYMPTOMS IN ACETYLCHOLINE RECEPTOR AUTOANTIBODY-POSITIVE PATIENTS OVER 52 WEEKS
Amgen (NASDAQ:AMGN) announced positive 52-week data from the Phase 3 MINT trial for UPLIZNA® in treating generalized myasthenia gravis (gMG). The trial demonstrated significant improvement in patients with acetylcholine receptor autoantibody-positive (AChR+) gMG using just two doses yearly after initial loading.
Key findings include:
- 72.3% of AChR+ patients on UPLIZNA achieved ≥3 point improvement in MG-ADL score vs 45.2% for placebo
- Significant change in baseline MG-ADL score (adjusted difference -2.8)
- 69.2% of UPLIZNA patients improved ≥3 points in QMG score vs 41.8% for placebo
The trial was notable as the first Phase 3 study for a biologic incorporating corticosteroid tapering in its protocol. No new safety concerns were identified, with common adverse events including infusion-related reactions, nasopharyngitis, and urinary tract infections. Regulatory filing is expected to complete in H1 2025.
Amgen (NASDAQ:AMGN) ha annunciato dati positivi a 52 settimane dal trial di Fase 3 MINT per UPLIZNA® nel trattamento della miastenia gravis generalizzata (gMG). Il trial ha dimostrato un significativo miglioramento nei pazienti con autoanticorpi contro il recettore dell'acetilcolina (AChR+) gMG, utilizzando solo due dosi annuali dopo il caricamento iniziale.
I risultati chiave includono:
- Il 72,3% dei pazienti AChR+ trattati con UPLIZNA ha raggiunto un miglioramento di ≥3 punti nel punteggio MG-ADL rispetto al 45,2% del gruppo placebo
- Cambiamento significativo nel punteggio MG-ADL di base (differenza aggiustata -2,8)
- Il 69,2% dei pazienti trattati con UPLIZNA ha mostrato un miglioramento di ≥3 punti nel punteggio QMG rispetto al 41,8% del placebo
Il trial è stato notevole in quanto il primo studio di Fase 3 per un biologico che incorpora la riduzione dei corticosteroidi nel suo protocollo. Non sono state identificate nuove preoccupazioni per la sicurezza, con eventi avversi comuni che includono reazioni legate all'infusione, nasofaringite e infezioni del tratto urinario. Si prevede che la presentazione regolatoria si completi nella prima metà del 2025.
Amgen (NASDAQ:AMGN) anunció datos positivos de 52 semanas del ensayo de Fase 3 MINT para UPLIZNA® en el tratamiento de la miastenia gravis generalizada (gMG). El ensayo demostró una mejora significativa en pacientes con autoanticuerpos contra el receptor de acetilcolina (AChR+) gMG, utilizando solo dos dosis anuales después de la carga inicial.
Los hallazgos clave incluyen:
- El 72,3% de los pacientes AChR+ en UPLIZNA lograron una mejora de ≥3 puntos en la puntuación MG-ADL frente al 45,2% del placebo
- Cambio significativo en la puntuación MG-ADL basal (diferencia ajustada -2,8)
- El 69,2% de los pacientes de UPLIZNA mejoraron ≥3 puntos en la puntuación QMG frente al 41,8% del placebo
El ensayo fue notable como el primer estudio de Fase 3 para un biológico que incorpora la reducción de corticosteroides en su protocolo. No se identificaron nuevas preocupaciones de seguridad, con eventos adversos comunes que incluyen reacciones relacionadas con la infusión, nasofaringitis e infecciones del tracto urinario. Se espera que la presentación regulatoria se complete en la primera mitad de 2025.
암젠 (NASDAQ:AMGN)은 UPLIZNA®의 일반화된 중증 근무력증(gMG) 치료를 위한 3상 MINT 시험의 52주 긍정적인 데이터를 발표했습니다. 이 시험은 초기 로딩 후 연간 단 두 번의 용량만으로 AChR+ gMG 환자에서 상당한 개선을 보여주었습니다.
주요 발견 사항은 다음과 같습니다:
- UPLIZNA를 투여받은 AChR+ 환자의 72.3%가 위약의 45.2%에 비해 MG-ADL 점수에서 ≥3점 개선을 달성했습니다.
- 기초 MG-ADL 점수에서 유의미한 변화 (조정된 차이 -2.8)
- UPLIZNA 환자의 69.2%가 위약의 41.8%에 비해 QMG 점수에서 ≥3점 개선을 보였습니다.
이 시험은 프로토콜에 코르티코스테로이드 감량을 포함한 첫 번째 3상 생물학적 연구로 주목받았습니다. 새로운 안전성 문제는 발견되지 않았으며, 일반적인 부작용으로는 주입 관련 반응, 비인두염 및 요로 감염이 포함되었습니다. 규제 제출은 2025년 상반기 완료될 것으로 예상됩니다.
Amgen (NASDAQ:AMGN) a annoncé des données positives sur 52 semaines de l'essai de phase 3 MINT pour UPLIZNA® dans le traitement de la myasthénie grave généralisée (gMG). L'essai a démontré une amélioration significative chez les patients avec des autoanticorps contre le récepteur de l'acétylcholine (AChR+) gMG, utilisant seulement deux doses par an après le chargement initial.
Les principales conclusions comprennent :
- 72,3 % des patients AChR+ sous UPLIZNA ont atteint une amélioration de ≥3 points au score MG-ADL contre 45,2 % pour le placebo
- Changement significatif dans le score MG-ADL de base (différence ajustée -2,8)
- 69,2 % des patients UPLIZNA ont amélioré de ≥3 points au score QMG contre 41,8 % pour le placebo
L'essai est remarquable en tant que première étude de phase 3 pour un biologique intégrant une réduction des corticostéroïdes dans son protocole. Aucune nouvelle préoccupation en matière de sécurité n'a été identifiée, les événements indésirables courants comprenant des réactions liées à l'infusion, une nasopharyngite et des infections des voies urinaires. Le dépôt réglementaire devrait être finalisé au premier semestre 2025.
Amgen (NASDAQ:AMGN) hat positive 52-Wochen-Daten aus der Phase-3-Studie MINT für UPLIZNA® zur Behandlung der generalisierten Myasthenia gravis (gMG) bekannt gegeben. Die Studie zeigte eine signifikante Verbesserung bei Patienten mit acetylcholinrezeptor-Autoantikörper-positiver (AChR+) gMG, die nur zwei Dosen jährlich nach der initialen Ladebehandlung erhielten.
Wichtige Ergebnisse umfassen:
- 72,3% der AChR+-Patienten unter UPLIZNA erreichten eine Verbesserung von ≥3 Punkten im MG-ADL-Score im Vergleich zu 45,2% bei Placebo
- Signifikanter Unterschied im Ausgangswert des MG-ADL-Scores (angepasste Differenz -2,8)
- 69,2% der UPLIZNA-Patienten verbesserten sich um ≥3 Punkte im QMG-Score im Vergleich zu 41,8% bei Placebo
Die Studie war bemerkenswert, da sie die erste Phase-3-Studie für ein Biologikum war, das eine Dosisreduktion von Kortikosteroiden in sein Protokoll einbezog. Es wurden keine neuen Sicherheitsbedenken festgestellt, wobei häufige unerwünschte Ereignisse Infusionsreaktionen, Nasopharyngitis und Harnwegsinfektionen umfassten. Die regulatorische Einreichung wird voraussichtlich im ersten Halbjahr 2025 abgeschlossen sein.
- Strong efficacy with 72.3% of AChR+ patients showing significant improvement vs 45.2% for placebo
- Convenient twice-yearly dosing schedule after initial loading dose
- First Phase 3 trial incorporating corticosteroid tapering protocol
- FDA granted Orphan Drug Designation for gMG treatment
- Regulatory approval still pending with submission not expected until H1 2025
- Presence of adverse events including infusion-related reactions
Insights
Amgen's positive 52-week MINT trial results for UPLIZNA represent a significant commercial opportunity that could substantially expand the drug's market beyond its current NMOSD indication. The demonstrated efficacy in acetylcholine receptor autoantibody-positive (AChR+) patients is particularly valuable as these patients represent approximately 80% of the gMG population. With an estimated 60,000-80,000 gMG patients in the U.S. alone, this presents a substantial addressable market.
The drug's differentiating factor is its twice-yearly dosing regimen after initial loading, which offers a compelling convenience advantage over competitors requiring more frequent administration. This could drive both patient preference and adherence, potentially commanding premium pricing and favorable formulary placement. The strong efficacy data - with 72.3% of patients achieving clinically meaningful improvement in activities of daily living scores versus 45.2% for placebo - supports a competitive clinical profile.
From a regulatory perspective, the Orphan Drug Designation and planned H1 2025 submission timeline create a clear path to potential commercialization. This aligns strategically with Amgen's expanding neuroscience portfolio following the Horizon acquisition, potentially creating commercial synergies with the company's existing infrastructure.
The multiple near-term catalysts, including the upcoming PDUFA date for IgG4-RD (April 3, 2025) and the gMG filing, provide sequential opportunities for UPLIZNA to expand into different rare disease markets, potentially establishing it as a multi-indication blockbuster within Amgen's portfolio.
The 52-week MINT trial results demonstrate robust and durable efficacy of UPLIZNA in AChR+ generalized myasthenia gravis, potentially addressing significant unmet needs in this patient population. The data shows clinically meaningful improvements across both functional measures, with 72.3% of treated patients achieving significant improvement in daily activities compared to 45.2% with placebo.
What's particularly significant from a clinical perspective is the successful corticosteroid taper protocol integrated into the study design. As the first Phase 3 trial for a biologic to incorporate this element, it addresses one of the most challenging aspects of gMG management – reducing dependency on steroids while maintaining symptom control. This feature alone could represent a paradigm shift in treatment approaches.
UPLIZNA's B-cell depleting mechanism offers a distinct therapeutic approach compared to complement inhibitors and acetylcholinesterase inhibitors currently available. This mechanistic diversity is valuable for patients who don't respond adequately to existing options. The twice-yearly maintenance dosing regimen following initial loading represents a substantial convenience advantage that could significantly improve treatment adherence and quality of life.
The consistent safety profile, primarily characterized by infusion-related reactions, nasopharyngitis and urinary tract infections, suggests manageable tolerability similar to its approved NMOSD indication. This predictable safety profile is particularly important for a chronic condition requiring long-term treatment.
If approved, UPLIZNA would expand the armamentarium available to neurologists treating this challenging autoimmune condition, offering a new option with demonstrated benefits in improving patients' ability to perform daily activities – the ultimate goal of gMG treatment.
Patients Reported Improvement in Ability to Conduct Daily Activities with Twice-Yearly Dosing*
Late-Breaking Data to be Presented at AAN 2025
The Phase 3 MINT trial, which was a randomized-control trial, evaluated UPLIZNA in muscle-specific kinase autoantibody-positive (MuSK+) and AChR+ gMG patients, with the MuSK+ group followed for 26 weeks and the AChR+ group followed for 52 weeks. The trial demonstrated continued improvement in efficacy of UPLIZNA compared to placebo (adjusted difference, −2.8,
As previously disclosed at the 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting, the trial met its primary endpoint, with a statistically significant change from baseline in MG-ADL score for UPLIZNA (-4.2) compared with placebo (-2.2) (difference: –1.9, p<0.0001) at Week 26 for the combined study population.
"The 52-week MINT trial results highlight the potential for a new standard of care in gMG, offering durable symptom relief with a simplified treatment regimen," said Jay Bradner, M.D., executive vice president of Research and Development at Amgen. "These findings reinforce UPLIZNA's ability to provide sustained symptom relief with just two doses per year—an important advancement for patients living with generalized myasthenia gravis—while underscoring our commitment to developing transformative therapies for people facing complex autoimmune diseases."
Change from baseline in the Quantitative Myasthenia Gravis (QMG) score was also greater for patients in the UPLIZNA group as compared to placebo at Week 52 (adjusted difference, −4.3,
MINT was the first and only Phase 3 trial for a biologic to incorporate a corticosteroid taper into its protocol. Patients who entered the study taking corticosteroids were tapered down starting at Week 4 to prednisone 5 mg per day by Week 24.
"I'm looking forward to further examining the 52-week MINT data with my colleagues in the neurology community at AAN," said Richard J. Nowak, M.D., M.S., global principal study investigator and director of the Myasthenia Gravis Clinic at Yale University. "These results showed that UPLIZNA consistently relieved burdensome symptoms and improved activities of daily living for gMG patients."
No new safety signals were identified. The overall TEAE profile during the study period is consistent with the known safety profile for the approved indication (NMOSD). The most common adverse events included infusion-related reactions, nasopharyngitis and urinary tract infections.
UPLIZNA is currently approved for the treatment of adult patients with anti-aquaporin-4 (AQP4) antibody positive neuromyelitis optica spectrum disorder (NMOSD) and is under priority FDA review for the treatment of Immunoglobulin G4-related disease (IgG4-RD) with a PDUFA date of April 3, 2025. The FDA has granted UPLIZNA Orphan Drug Designation for the treatment of gMG. Regulatory filing activities are underway with submission anticipated to be complete in H1 2025.
*After an initial loading dose.
About the MINT Trial
The MINT trial is a randomized, double-blind, placebo-controlled, parallel-group trial (NCT04524273) evaluating the efficacy and safety of UPLIZNA in adults with gMG. The trial enrolled 238 adults with gMG, including 190 patients who are acetylcholine receptor autoantibody-positive (AChR+) and 48 patients who are muscle-specific kinase autoantibody-positive (MuSK+).
Eligibility criteria at screening and randomization included a Myasthenia Gravis Foundation of America (MGFA) classification of II, III, or IV disease, MG-ADL score between 6 and 10 with greater than
The primary endpoint was change from baseline in MG-ADL score at Week 26 in the combined population. Key secondary endpoints included change from baseline in QMG scores in the combined study population; change from baseline in MG-ADL score at Week 26 for the AChR+ cohort and separately the MuSK+ cohort; and change from baseline in QMG score at Week 26 for the AChR+ cohort and separately the MuSK+ cohort. Patients who entered the study taking a corticosteroid were tapered down to prednisone 5 mg a day, starting at Week 4 to Week 24. The MINT trial also includes an optional three-year open-label treatment period.
About Generalized Myasthenia Gravis (gMG)
Generalized myasthenia gravis (gMG) is a rare, chronic, B-cell-mediated autoimmune disorder that impairs neuromuscular communication and can cause muscle weakness, trouble breathing, difficulty swallowing and impaired speech and vision.2-4
Approximately
The prevalence and incidence of gMG are increasing worldwide.6 There are between 80,000 and 100,000 patients with myasthenia gravis in the
B cells are central to the pathogenesis of gMG. The disease is thought to be primarily driven by pathogenic CD19+ plasmablasts and plasma cells that target critical proteins in the neuromuscular junction.2-4
About UPLIZNA® (inebilizumab-cdon)
UPLIZNA is a humanized monoclonal antibody (mAb) that causes targeted and sustained depletion of key cells that contribute to underlying disease process (autoantibody-producing CD19+ B cells, including plasmablasts and some plasma cells). The precise mechanism by which UPLIZNA exerts its therapeutic effects is unknown. After two initial infusions, patients need one dose of UPLIZNA every six months.
About UPLIZNA in NMOSD
INDICATION AND IMPORTANT SAFETY INFORMATION
INDICATION
UPLIZNA (inebilizumab-cdon) is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.
IMPORTANT SAFETY INFORMATION
UPLIZNA is contraindicated in patients with:
- A history of life-threatening infusion reaction to UPLIZNA
- Active hepatitis B infection
- Active or untreated latent tuberculosis
WARNINGS AND PRECAUTIONS
Infusion Reactions: UPLIZNA can cause infusion reactions, which can include headache, nausea, somnolence, dyspnea, fever, myalgia, rash, or other symptoms. Infusion reactions were most common with the first infusion but were also observed during subsequent infusions. Administer pre-medication with a corticosteroid, an antihistamine, and an anti-pyretic.
Infections: The most common infections reported by UPLIZNA-treated patients in the randomized and open-label periods included urinary tract infection (
Increased immunosuppressive effects are possible if combining UPLIZNA with another immunosuppressive therapy.
The risk of Hepatitis B Virus (HBV) reactivation has been observed with other B-cell-depleting antibodies. Perform HBV screening in all patients before initiation of treatment with UPLIZNA. Do not administer to patients with active hepatitis.
Although no confirmed cases of Progressive Multifocal Leukoencephalopathy (PML) were identified in UPLIZNA clinical trials, JC virus infection resulting in PML has been observed in patients treated with other B-cell-depleting antibodies and other therapies that affect immune competence. At the first sign or symptom suggestive of PML, withhold UPLIZNA and perform an appropriate diagnostic evaluation.
Patients should be evaluated for tuberculosis risk factors and tested for latent infection prior to initiating UPLIZNA.
Vaccination with live-attenuated or live vaccines is not recommended during treatment and after discontinuation, until B-cell repletion.
Reduction in Immunoglobulins: There may be a progressive and prolonged hypogammaglobulinemia or decline in the levels of total and individual immunoglobulins such as immunoglobulins G and M (IgG and IgM) with continued UPLIZNA treatment. Monitor the level of immunoglobulins at the beginning, during, and after discontinuation of treatment with UPLIZNA until B-cell repletion especially in patients with opportunistic or recurrent infections.
Fetal Risk: May cause fetal harm based on animal data. Advise females of reproductive potential of the potential risk to a fetus and to use an effective method of contraception during treatment and for 6 months after stopping UPLIZNA.
Adverse Reactions: The most common adverse reactions (at least
About Amgen
Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases.
In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average®, and it is also part of the Nasdaq-100 Index®, which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization.
For more information, visit Amgen.com and follow Amgen on X, LinkedIn, Instagram, YouTube and Threads.
Amgen Forward-Looking Statements
This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), our acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on our acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.
No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future.
Even when clinical trials are successful, regulatory authorities may question the sufficiency for approval of the trial endpoints we have selected. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market.
Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the
The scientific information discussed in this news release relating to new indications for our product is preliminary and investigative and is not part of the labeling approved by the
CONTACT: Amgen,
Madison Howard, 773-636-4910 (media)
Elissa Snook, 609-251-1407 (media)
Justin Claeys, 805-313-9775 (investors)
References
- Nowak R, Phase 3 Myasthenia Gravis Inebilizumab Trial (MINT): Efficacy Data in AChR+ Generalized MG Subpopulation Through Week-52 [Late-breaking oral presentation]. To be presented at American Academy of Neurology Annual Meeting (5-9 April 2025). Available at: www.aan.com/msa/Public/Events/AbstractDetails/61470
- Yi, J. S., Guptill, J. T., Stathopoulos, P., Nowak, R. J., & O'Connor, K. C. (2018). B cells in the pathophysiology of myasthenia gravis. Muscle Nerve, 57(2):172-184.
- Willcox H. N., Newsom-Davis, J., & Calder, L. R. (1984). Cell types required for anti-acetylcholine receptor antibody synthesis by cultured thymocytes and blood lymphocytes in myasthenia gravis. Clinical and Experimental Immunology., 58:97-106.
- Stathopoulos P., Kumar, A., Nowak, R. J., & O'Connor, K. C. (2017). Autoantibody-producing plasmablasts after B cell depletion identified in muscle-specific kinase myasthenia gravis. JCI Insight, 2(17):e94263.
- Lazaridis K., & Tzartos, S. J. (2020). Autoantibody Specificities in Myasthenia Gravis; Implications for Improved Diagnostics and Therapeutics. Frontiers in Immunology, 11:212.
- Dresser L., Wlodarski, R., Rezania, K., & Soliven, B. (2021). Myasthenia Gravis: Epidemiology, Pathophysiology and Clinical Manifestations. J Clin Med, 10(11):2235.
- Ye et al. Frontiers in Neurology. (2024);15:1339167.
- Rodrigues E., Umeh, E., Aishwarya, Navaratnarajah, N., Cole, A., & Moy, K. (2024). Incidence and prevalence of myasthenia gravis in
the United States : A claims-based analysis. Muscle Nerve, 69(2):166-171. - Hehir, M. K., & Silvestri, N. J. (2018). Generalized myasthenia gravis: classification, clinical presentation, natural history, and epidemiology. Neurologic Clinics, 36:253-60.
- Bubuioc, A. M., Kudebayeva, A., Turuspekova, S., Lisnic, V., & Leone, M. A. (2021). The epidemiology of myasthenia gravis. Journal of Medicine and Life, 14(1):7-16.
View original content to download multimedia:https://www.prnewswire.com/news-releases/uplizna-inebilizumab-cdon-significantly-improves-generalized-myasthenia-gravis-symptoms-in-acetylcholine-receptor-autoantibody-positive-patients-over-52-weeks-302401082.html
SOURCE Amgen